Please ensure Javascript is enabled for purposes of website accessibility

Could Merck's New Antiviral Be the Next Big COVID Treatment?

By Morgan McSweeney - Mar 30, 2021 at 6:32AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Merck and Ridgeback Biotherapeutics' oral pill is still in clinical testing, but preliminary results are promising.

Lots of names in pharma and biotech -- both big and small -- have jumped into the fight against COVID-19. Pharma giant Merck (MRK 1.58%) and privately owned Ridgeback Biotherapeutics, for example, chose to dive into the fray together in order to develop an antiviral against the novel coronavirus. 

Their potential oral pill, molnupiravir, has produced positive results so far in clinical trials. But what exactly do the results mean, and how much farther does the drug have to go before it can be distributed to the public?

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$93.55 (1.58%) $1.46

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.